GlassScriptPhysician profile
Jennifer S Mueller
NPI 1922738145
$1,059.54
in general payments reported to CMS, 2019-2025
15 companies · $558 in 2025
The $558 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $107 · 2023: $150 · 2024: $245 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.94 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Amgen INC. | $262.35 | 2024-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $140.25 | 2022-2025 | |
| Novo Nordisk INC | $65.43 | 2025 | Ozempic, Rybelsus |
| Philips North America LLC | $60.62 | 2025 | Encore |
| Lilly USA, LLC | $52.99 | 2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $49.30 | 2024-2025 | Shingrix, Bexsero, Arexvy |
| Novartis Pharmaceuticals Corporation | $42.09 | 2025 | |
| Sumitomo Pharma America, INC. | $24.92 | 2025 | Gemtesa |
| Viatris Specialty LLC | $21.51 | 2025 | Yupelri |
| Verona Pharma, INC. | $20.03 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $18.09 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $16.86 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.01 | 2025 | Voquezna |
| Organon LLC | $7.15 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.